UCSF STUDY FINDS THAT AN OSTEOPOROSIS PREVENTION DRUG REDUCES THE RISK OF BREAST CANCER BY 76 PERCEN
Researchers at the University of California, San Francisco report that a novel osteoporosis prevention drug, called raloxifene, reduced the risk of invasive breast cancer in postmenopausal women with osteoporosis by 76 percent after forty months of treatment.